The FSA’s 2025–26 novel‑food recommendations could bring the UK’s first authorised edible CBD products, unlocking potential for no/low‑alcohol CBD drinks in pubs while creating new compliance duties on labelling, THC limits and licensing. This article outlines the market opportunity, regulatory guardrails, clinical evidence to date and practical risks operators should manage.

More UK women are trying CBD topicals and suppositories for menstrual and pelvic pain, but the FSA’s 10 mg/day advice and emerging 2024–2026 evidence call for caution. This article summarises current observational findings, regulatory guidance, safety considerations including potential drug interactions, and practical 'start low, go slow' steps for those considering topical routes.

This article summarises UK and international evidence (2020–2026) on low‑dose CBD for adults with ADHD: what registry analyses, small trials and systematic reviews tell us about efficacy, dosing bands, safety and drug interactions, and the practical workplace guidance gap.